GENEVA — The World Health Organization confirmed that the ongoing Bundibugyo virus disease (BVD) epidemic centered in the Democratic Republic of the Congo has become the second-deadliest Ebola outbreak in world history, with confirmed infections climbing to 8,728 and fatalities reaching 4,205. The emergency widened over the past 48 hours after health authorities in Kenya confirmed the nation's first fatal imported case involving a citizen who traveled overland through Uganda before dying in a Nairobi isolation ward. International health teams are now monitoring dozens of contacts across transit hubs as transmission remains intense in eastern DRC provinces, including Ituri and North Kivu, where active conflict and community displacement continue to hamper containment efforts.

Unlike the better-known Zaire ebolavirus strain, for which approved vaccines such as Ervebo and monoclonal antibody treatments exist, there are currently no licensed vaccines or targeted therapeutics approved for Bundibugyo virus disease. In response, the WHO Emergency Committee, which previously designated the crisis a Public Health Emergency of International Concern (PHEIC), underscored that clinical management currently relies almost exclusively on early supportive care and fluid resuscitation. WHO emergency response officials warned that high population mobility along regional trade corridors creates an imminent risk of further regional spillover, while several humanitarian personnel have already required emergency medical evacuations to specialized biocontainment facilities across Europe.

Global health authorities and biopharmaceutical consortia are now mobilizing emergency clinical trial protocols to evaluate experimental candidate vaccines and pan-filovirus antivirals directly in the field under compassionate-use frameworks. The United Nations Office for the Coordination of Humanitarian Affairs has disbursed emergency relief funds to fortify border surveillance, infection control supplies, and contact-tracing networks in neighboring countries. With case fatality rates hovering near 50%, epidemiologists warn that unless regional borders coordinate rigorous screening and clinical trials deliver rapid therapeutic interventions, containment in Central and East Africa could face months of prolonged crisis.